- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04809012
Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
March 9, 2022 updated by: Sorrento Therapeutics, Inc.
An Open-label, Multicenter, Phase 2 Basket Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
This study evaluates the efficacy of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected solid tumors.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, multicenter, Phase 2 basket study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of STI-3031, an anti-PD-L1 antibody, in patients with selected RRSTs.
All participants will receive STI-3031 20 mg/kg every 2 weeks (Q2W) via IV infusion over approximately 60 minutes.
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score ≤ 2
- Has histologically- or cytologically-confirmed relapsing or refractory solid tumor and subject has exhausted all approved options that may, in the investigator's opinion, produce clinical benefit.
- Has at least one measurable disease per RECIST 1.1
- May have been treated with radiation therapy (RT) provided there is measurable disease outside the field of RT. Prior systemic RT must be completed at least 4 weeks before the first dose of study intervention. Prior focal radiotherapy must be completed at least 2 weeks before the first dose of study intervention. No radiopharmaceuticals are permitted within 8 weeks before the first dose of study intervention.
- Life expectancy of at least 16 weeks per investigator assessment
- Must have adequate hematologic, hepatic and renal function as assessed by specific laboratory criteria
- Willing to sign the informed consent form and comply with the study schedule and all other protocol requirements
- Females of childbearing potential (FCBP) must have a negative pregnancy test during the Screening Period prior to treatment. All heterosexually active FCBP and all heterosexually active male patients must agree to use effective double barrier methods of birth control throughout the study.
- At time of the first dose of study intervention, at least 14 days or 5 half-lives, whichever is shorter, since the last chemotherapy, immunotherapy, biological or investigational therapy, and have recovered from toxicities associated with such treatment to < Grade 2.
Exclusion Criteria:
- Previously treated with an anti-PD-L1 or anti-PD-1 antibody
- Known presence of symptomatic central nervous system (CNS) metastases unless considered adequately treated and off corticosteroids and/or anticonvulsant therapy for at least 2 weeks prior to first dose of study intervention.
- Prior allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. Prior autologous HSCT is allowed.
- Any other malignancy, excluding basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, or localized prostate cancer, from which the participant has not been disease-free for at least 2 years.
- Any active autoimmune disease requiring treatment within the past 3 months or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for participants with vitiligo, hormone replacement therapy for stable thyroid diseases and Type 1 diabetes mellitus.
- Evidence of active or latent tuberculosis (TB) infection
- Known viral infection with COVID-19, hepatitis B virus (HBV) hepatitis C virus (HCV), unless participant, as applicable, is negative on RT-PCR or rapid antigen tests, has been vaccinated, and has completed curative antiviral treatment and viral load is below the limit of quantification.
- Known active viral infection with human immunodeficiency virus (HIV)
- Active infection (viral, bacterial, or fungal) requiring intravenous (IV) systemic therapy within 14 days prior to the first dose of study intervention.
- Evidence of bleeding diathesis or coagulopathy.
- Conditions requiring chronic steroid use (> 10 mg/day of prednisone or equivalent).
- Recent history of attenuated viral vaccination within 30 days prior to the first dose of study intervention.
- Herbal preparations/medications are not allowed throughout the treatment period unless first discussed with and approved by the Medical Monitor.
- History of severe hypersensitivity reactions to other monoclonal antibodies or known hypersensitivity to the study intervention or its excipients.
- Known current drug or alcohol abuse
- Major surgical procedures ≤ 28 days prior to the first dose of study intervention, or minor surgical procedures ≤ 7 days prior to the first dose of study intervention. No waiting is required following port-a-catch placement or similar venous access device.
- Pregnant or lactating or intending on either during the study
- Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure NYHA III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 3 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).
- Underlying medical conditions that, in the Investigator's opinion, will make the administration of study intervention hazardous or obscure the interpretation of toxicity determination or AEs, including psychiatric illness or social situation that would preclude study compliance.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: STI-3031
20 mg/kg STI-3031 administered intravenously Q2W
|
STI-3031 is an anti-PD-L1 antibody
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate
Time Frame: Baseline through study completion at up to approximately 3 years
|
Objective response rate (ORR) as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
|
Baseline through study completion at up to approximately 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as assessed by incidence and severity of adverse events
Time Frame: Baseline through study completion at up to approximately 3 years
|
Incidence of treatment-emergent adverse events and their relationships to STI-3031
|
Baseline through study completion at up to approximately 3 years
|
Duration of Response
Time Frame: Baseline through study completion at up to approximately 3 years
|
Duration of response (DOR) as assessed using RECIST 1.1
|
Baseline through study completion at up to approximately 3 years
|
Complete response rate and duration
Time Frame: Baseline through study completion at up to approximately 3 years
|
Complete response (CR) rate and duration of CR as assessed using RECIST 1.1
|
Baseline through study completion at up to approximately 3 years
|
Progression-Free Survival
Time Frame: Baseline through study completion at up to approximately 3 years
|
Progression-free survival (PFS) and 12-month PFS as assessed using RECIST 1.1
|
Baseline through study completion at up to approximately 3 years
|
Event-free survival
Time Frame: Baseline through study completion at up to approximately 3 years
|
Event-free survival (EFS) as assessed using RECIST 1.1
|
Baseline through study completion at up to approximately 3 years
|
Overall survival
Time Frame: Baseline through study completion at up to approximately 3 years
|
Overall survival (OS) as assessed using RECIST 1.1
|
Baseline through study completion at up to approximately 3 years
|
Time to next treatment
Time Frame: Baseline through study completion at up to approximately 3 years
|
Time to next treatment (TTNT)
|
Baseline through study completion at up to approximately 3 years
|
Incidence of anti-drug antibody
Time Frame: Baseline through study completion at up to approximately 3 years
|
Incidence of anti-drug antibody (ADA) and correlation with exposure and activity as measured using serum titers of anti-STI-3031 antibodies
|
Baseline through study completion at up to approximately 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 1, 2021
Primary Completion (Anticipated)
June 1, 2024
Study Completion (Anticipated)
June 1, 2024
Study Registration Dates
First Submitted
March 13, 2021
First Submitted That Met QC Criteria
March 18, 2021
First Posted (Actual)
March 22, 2021
Study Record Updates
Last Update Posted (Actual)
March 25, 2022
Last Update Submitted That Met QC Criteria
March 9, 2022
Last Verified
March 1, 2022
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
Clinical Trials on STI-3031
-
Sorrento Therapeutics, Inc.WithdrawnDiffuse Large B Cell Lymphoma | Biliary Tract Cancer | Peripheral T Cell Lymphoma | Extranodal NK T Cell Lymphoma, Nasal
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMelanoma | Metastatic Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Metastatic MelanomaUnited States
-
Dong-A ST Co., Ltd.CompletedLymphoma | Solid TumorKorea, Republic of
-
Zhejiang ACEA Pharmaceutical Co. Ltd.Completed
-
Zhejiang ACEA Pharmaceutical Co. Ltd.Recruiting
-
Children's Hospital Medical Center, CincinnatiEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingChlamydia | GonorrheaUnited States
-
Sorrento Therapeutics, Inc.RecruitingMultiple MyelomaUnited States
-
Columbia UniversityCompletedSexually Transmitted InfectionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnSTI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL AmyloidosisAcute Myeloid Leukemia (AML) | Refractory T Acute Lymphoblastic LeukemiaUnited States
-
OhioHealthTerminatedSexually Transmitted DiseasesUnited States